Form 4: Inhibitor Therapeutics Director Michael Jerman Acquires 50,000 Shares of Common Stock

Director Michael Jerman acquired 50,000 shares of Inhibitor Therapeutics common stock on April 1, 2024, as compensation under the company's 2014 Equity Incentive Plan.

Summary

• On April 1, 2024, Michael Jerman, a director of Inhibitor Therapeutics, Inc. (INTI), acquired 50,000 shares of common stock.
• The acquisition was made as compensation under the Issuer's 2014 Equity Incentive Plan.
• The price per share was $0.
• Following the transaction, Jerman directly owns 80,411 shares of Inhibitor Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing detailing a stock transaction. The director's acquisition could be seen as a slightly positive signal, but it's primarily an informational document.

Positives

• The acquisition of shares by a director could be seen as a positive sign, indicating confidence in the company's future.

Industry Context

This filing is a routine disclosure related to insider transactions and is a common occurrence for publicly traded companies.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's investment in the company.

Key Dates

Keywords

Inhibitor Therapeutics, INTI, Michael Jerman, Director, Common Stock, Equity Incentive Plan, Beneficial Ownership, SEC Form 4